Fiche publication
Date publication
septembre 2020
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J,
Lien Pubmed
Résumé
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.
Référence
N. Engl. J. Med.. 2020 Sep 20;:
